Vaccaro O, Mancini F P, Ruffa G, Sabatino L, Colantuoni V, Riccardi G
Department of Clinical and Experimental Medicine Medical School, Federico II University, Naples, Italy.
Int J Obes Relat Metab Disord. 2000 Sep;24(9):1195-9. doi: 10.1038/sj.ijo.0801366.
To explore the association of the Pro12Ala mutation in the peroxisome proliferator-activated receptor gamma2 with severe obesity and the features of the metabolic syndrome in a population-based sample of Caucasians.
The study is based on a case-control design: 95 non-diabetic severely obese (body mass index, BMI > 35 kg/m2) cases and 280 normal weight (BMI < 25 kg/m2), age- and sex-matched controls selected from the same population were studied. Height, weight, waist circumference, as well as blood pressure were measured according to a standard protocol. BMI at age 25 y was calculated on the basis of current height and reported weight at age 25 y Biochemical measurements included fasting glucose, triglycerides, high-density lipoprotein cholesterol and insulin. DNA analysis was conducted by PCR and gel electrophoresis.
Age and gender distribution were similar in obese and normal weight participants. The percentage of people with the Pro12Ala mutation was not significantly different in obese or normal weight participants (20% and 15%, respectively; P = 0.32). Conversely, in obese participants with obesity starting in early adulthood (ie with BMI at age 25 above 26.9kg/m2 which represents the median of the whole obese group), the Pro12Ala mutation was observed significantly more frequently than in the normal weight controls (29% vs 15%; chi square = 4.5, P < 0.05; odds ratio 2.4; 95% CI 1.03-5.36). No association of the Pro12Ala variant with any of the component of the metabolic syndrome measured in the study was observed in either obese, juvenile obese or normal weight participants.
Results of this study indicate that the Pro12Ala mutation does not play a major role as a determinant of severe obesity and/or features of the metabolic syndrome in the general population. However, this mutation may be of greater importance as a contributor to early onset obesity.
在一项基于人群的白种人样本中,探讨过氧化物酶体增殖物激活受体γ2基因Pro12Ala突变与重度肥胖及代谢综合征特征之间的关联。
本研究采用病例对照设计:研究了95例非糖尿病重度肥胖患者(体重指数,BMI>35kg/m²)以及从同一人群中选取的280例体重正常(BMI<25kg/m²)、年龄和性别匹配的对照者。按照标准方案测量身高、体重、腰围以及血压。根据当前身高和报告的25岁时体重计算25岁时的BMI。生化指标检测包括空腹血糖、甘油三酯、高密度脂蛋白胆固醇和胰岛素。通过聚合酶链反应(PCR)和凝胶电泳进行DNA分析。
肥胖组和体重正常组参与者的年龄和性别分布相似。Pro12Ala突变者的百分比在肥胖组和体重正常组参与者中无显著差异(分别为20%和15%;P=0.32)。相反,在成年早期开始肥胖的肥胖参与者中(即25岁时BMI高于26.9kg/m²,这代表整个肥胖组的中位数),Pro12Ala突变的发生率显著高于体重正常的对照组(29%对15%;卡方=4.5,P<0.05;优势比2.4;95%可信区间为1.03 - 5.36)。在肥胖者、青少年肥胖者或体重正常的参与者中,均未观察到Pro12Ala变异与本研究中所测量的代谢综合征的任何组分之间存在关联。
本研究结果表明,Pro12Ala突变在一般人群中并非重度肥胖和/或代谢综合征特征的主要决定因素。然而,作为早发性肥胖的一个促成因素,该突变可能更为重要。